[{"orgOrder":0,"company":"L\u00e1szl\u00f3 Mangel","sponsor":"E-Group ICT Software Informatikai Zrt.","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Miscellaneous","year":"2020","type":"Inapplicable","leadProduct":"Selegiline Hydrochloride","moa":"Monoamine oxidase B","graph1":"Oncology","graph2":"Phase II","graph3":"L\u00e1szl\u00f3 Mangel","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Tablet","sponsorNew":"L\u00e1szl\u00f3 Mangel \/ E-Group ICT Software Informatikai Zrt.","highestDevelopmentStatusID":"8","companyTruncated":"L\u00e1szl\u00f3 Mangel \/ E-Group ICT Software Informatikai Zrt."}]

Find Clinical Drug Pipeline Developments & Deals for Selegiline

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          László Mangel

                          Country arrow
                          PackExpo
                          Not Confirmed

                          László Mangel

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Selegiline is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Prostatic Neoplasms, Castration-Resistant.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          October 14, 2020

                          Lead Product(s) : Selegiline Hydrochloride

                          Therapeutic Area : Oncology

                          Highest Development Status : Phase II

                          Sponsor : E-Group ICT Software Informatikai Zrt.

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Mood and Anxiety Research, Inc

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Mood and Anxiety Research, Inc

                          Country arrow
                          PackExpo
                          Not Confirmed

                          Details : Selegiline is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Borderline Personality Disorder.

                          Product Name : Undisclosed

                          Product Type : Miscellaneous

                          Upfront Cash : Inapplicable

                          July 31, 2013

                          Lead Product(s) : Selegiline Hydrochloride

                          Therapeutic Area : Psychiatry/Psychology

                          Highest Development Status : Phase III

                          Sponsor : Undisclosed

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank